TaiMed Biologics Inc.

Taipei Exchange 4147.TWO

TaiMed Biologics Inc. Gross Profit Margin for the year ending December 31, 2023: 45.80%

TaiMed Biologics Inc. Gross Profit Margin is 45.80% for the year ending December 31, 2023, a 19.54% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

TaiMed Biologics Inc. Gross Profit Margin for the year ending December 31, 2022 was 38.31%, a 88.68% change year over year.
TaiMed Biologics Inc. Gross Profit Margin for the year ending December 31, 2021 was 20.31%, a -54.33% change year over year.
TaiMed Biologics Inc. Gross Profit Margin for the year ending December 31, 2020 was 44.46%, a 36.19% change year over year.
TaiMed Biologics Inc. Gross Profit Margin for the year ending December 31, 2019 was 32.65%, a 496.32% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

Taipei Exchange: 4147.TWO

TaiMed Biologics Inc.

CEO	Mr. Chin-Ming Chang Ph.D.
IPO Date	June 20, 2012
Location	Taiwan
Headquarters	No. 607, Ruiguang Road
Employees	79
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals Vaccines

Description

TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes various drugs for the treatment and prevention of infectious diseases. The company develops and markets Ibalizumab (TMB-355) Intravenous Infusion, a humanized monoclonal antibody for the treatment of HIV-1 infection. It is also developing TMB-355 Intravenous Push, a humanized monoclonal antibody for the treatment of HIV-1 infection; TMB-355 Intramuscular Injection, a humanized monoclonal antibody intramuscular injection, which is in Phase III clinical trials for treating HIV-1; TMB-365, an anti-CD4 recombinant humanized monoclonal antibody, which completed Phase I clinical trials for treating HIV infections; and TMB-380, a neutralizing HIV-1 antibody. The company was incorporated in 2007 and is headquartered in Taipei, Taiwan.

Key trends

Past 5 years